3-aminoimidazo 1,2-a pyridine derivatives having an sglt1- and sglt2-inhibiting action for the treatment of type 1 and type 2 diabetes

Compounds of the formula I

• in which
• X1, X2, X3, X4, X5, X6 each, independently of one another, denote C—R7, N or C-Het,
• Y denotes O, S, N—R7 or N-Het,
• R1, R2, R3, R4, R5, R6, R7 each, independently of one another, independently denote H, A, OH, OA, NAA′, Hal, CN, NO2, O(CH2)mCONAA′, NA(CH2)mCONAA′, (CH2)mNAA′, O(CH2)mNAA′, O(CH2)mOA, O(C═O)(CH2)mNAA′, (C═O)O(CH2)mNAA′, NA(C═O)(CH2)mNAA′, (C═O)NA(CH2)mNAA′, CH2O(CH2)mNAA′, CH2OA or COOA,
• A, A′, A″ each, independently of one another, denote H, linear or branched alkyl having 1-10 C atoms which is unsubstituted or mono-, di- or trisubstituted by ═S, ═NR, ═O (carbonyl oxygen), NRR′, OH, CN, CONRR′ and/or NO2 and in which one, two or three CH2 groups may be replaced, independently of one another, by O, S, SO, SO2, NR,
• —OCO—, —NRCONR′—, —NRCO—, —COO—, —CONR—, —C≡C— groups and/or by —CH═CH— groups and/or, in addition, 1-20 H atoms may be replaced by F and/or Cl, or cyclic alkyl having 3-7 C atoms which is unsubstituted or mono-, di- or trisubstituted by ═S, ═NR, ═O (carbonyl oxygen), NRR′, OH, CN, CONRR′ and/or NO2 and in which one, two or three CH2 groups may be replaced, independently of one another, by O, S, SO, SO2, NR,
• —OCO—, —NRCONR′—, —NRCO—, —COO—, —CONR—, —C≡C— groups and/or by —CH═CH— groups and/or, in addition, 1-11 H atoms may be replaced by F and/or Cl,
• R, R′ each, independently of one another, denote H, linear or branched alkyl having 1-10 C atoms which is unsubstituted or mono-, di- or trisubstituted by ═S, ═NR, ═O (carbonyl oxygen), NH2, OH, CN, CONH2 and/or NO2 and in which one, two or three CH2 groups may be replaced, independently of one another, by O, S, SO, SO2, NH, NCH3, —OCO—, —NHCONH—, —NHCO—, —COO—,
• —CONH—, —NCH3CO—, CONCH3—, —C≡C— groups and/or by —CH═CH— groups and/or, in addition, 1-20 H atoms may be replaced by F and/or Cl, or cyclic alkyl having 3-7 C atoms which is unsubstituted or mono-, di- or trisubstituted by ═S, ═NR, ═O (carbonyl oxygen), NH2, OH, CN, CONH2 and/or NO2 and in which one, two or three CH2 groups may be replaced, independently of one another, by O, S, SO, SO2, NH, NCH3, —OCO—, —NHCONH—, —NHCO—, —COO—, —CONH—, —NCH3CO—, CONCH3— and/or by —CH═CH— groups and/or, in addition, 1-11 H atoms may be replaced by F and/or Cl,
• T denotes Ar or Het,
• Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di-, tri- or tetrasubstituted by A, Hal, OA, OH, SA, NAA′, SOA, SO2A, NO2, CN, COOA, COOH, CHO, COA, SO3H OCOA, CONAA′, NA′COA, NACONA′A″, NA′SO2A and/or SO2NAA′,
• Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be mono-, di- or trisubstituted by A, Hal, OA, OH, SA, NAA′, SOA, SO2A, NO2, CN, COOA, COOH, CHO, COA, SO3H OCOA, CONAA′, NA′COA, NACONA′A″, NA′SO2A, SO2NAA′, ═S, ═NR1 and/or ═O (carbonyl oxygen),
• Hal denotes F, Cl, Br or I,
• m denotes 1, 2 or 3,
• and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.